MedeliX
Start asking

insulin lispro

Humalog, Liprolog, Lyumjev (previously Liumjev) · ATC code A10AB04;A10AD04

Key facts
Active substance
insulin lispro
Drug class
Insulin analog
ATC code
A10AB04;A10AD04
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Humalog 100 units/ml solution for injection in vial / Humalog 100 units/ml solution for injection in cartridge / Humalog 100 units/ml KwikPen solution for injection in a pre-filled pen · Humalog Mix25 100 units/ml suspension for injection in vial / Humalog Mix25 100 units/ml suspension for injection in cartridge / Humalog Mix25 100 units/ml KwikPen suspension for injection in a pre-filled pen · Humalog Mix50 100 units/ml suspension for injection in cartridge / Humalog Mix50 100 units/ml KwikPen suspension for injection in a pre-filled pen · Humalog 200 units/ml KwikPen solution for injection in a pre-filled pen · Liprolog 100 units/ml, solution for injection in vial / Liprolog 100 units/ml, solution for injection in cartridge / Liprolog 100 units/ml KwikPen, solution for injection in a pre-filled pen · Liprolog Mix25 100 units/ml, suspension for injection in cartridge / Liprolog Mix25 100 units/ml KwikPen, suspension for injection in a pre-filled pen · Liprolog Mix50 100 units/ml, suspension for injection in cartridge / Liprolog Mix50 100 units/ml KwikPen, suspension for injection in a pre-filled pen · Liprolog 200 units/ml KwikPen, solution for injection in a pre-filled pen
Marketing authorisation holder
Eli Lilly Nederland B.V.
Information as of
2026-10-27

Key facts

Insulin lispro is a rapid-acting human insulin analogue (e.g. Humalog, Liprolog, Lyumjev) for diabetes mellitus requiring insulin; the Mix25 and Mix50 forms combine it with an intermediate-acting component.

What it is used for

  • Humalog/Liprolog: adults and children with diabetes mellitus requiring insulin, and initial stabilisation
  • Humalog/Liprolog Mix25 and Mix50: diabetes mellitus requiring insulin
  • Lyumjev 100 units/mL: diabetes mellitus in adults, adolescents and children aged 1 year and above; Lyumjev 200 units/mL in adults only

Dosing

  • Dose determined by the physician according to the patient's requirement
  • Humalog/Liprolog: shortly before meals, or soon after when necessary; duration of action 2 to 5 hours subcutaneously
  • Lyumjev: zero to two minutes before the start of the meal, with the option of up to 20 minutes after starting
  • Mix25/Mix50: subcutaneous injection only, never intravenously
  • Humalog 100 units/ml may be given intravenously if necessary (e.g. ketoacidosis, perioperatively)
  • Insulin requirements may be reduced in renal or hepatic impairment
  • 200 units/ml: never transfer from the KwikPen to a syringe (risk of overdose)

Contraindications

  • Hypersensitivity to the active substance or any excipient
  • Hypoglycaemia

Important warnings

  • Transfer to another insulin only under strict medical supervision; dose changes may be needed
  • Risk of hypo- and hyperglycaemia; warning symptoms may be altered
  • Combination with pioglitazone: cases of cardiac failure reported
  • To avoid medication errors, check the insulin label before each injection
  • Batch number should be recorded for traceability

Side effects

  • Hypoglycaemia is the most frequent undesirable effect; severe hypoglycaemia may lead to loss of consciousness and, in extreme cases, death
  • Local and systemic allergy
  • Lipodystrophy and cutaneous amyloidosis at injection sites

Interactions

  • Increased insulin requirement with e.g. oral contraceptives, corticosteroids, thyroid replacement, danazol, beta2 stimulants
  • Reduced insulin requirement with e.g. oral hypoglycaemics, salicylates, sulpha antibiotics, MAOIs, SSRIs, ACE inhibitors, angiotensin II receptor blockers, beta-blockers, octreotide, alcohol
  • Pioglitazone: consider the risk of cardiac failure

Pregnancy and breastfeeding

  • No adverse effect on pregnancy indicated; insulin requirements usually fall in the first trimester and rise in the second and third
  • Breast-feeding patients may need adjustments in insulin dose, diet or both

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

Source: European Medicines Agency (EMA), product information

Brand names in 3 more European countries
Iceland
Bysumlog, Humalog, Insulin Lispro, Liprolog, Lyumjev
Liechtenstein
Bysumlog, Humalog, Insulin Lispro, Liprolog, Lyumjev
Norway
Bysumlog, Humalog, Insulin Lispro, Liprolog, Lyumjev

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Related calculators

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Humalog – EPAR, Product Information (Detailed information on this medicinal product is available ). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/humalog-epar-product-information_en.pdf
  2. European Medicines Agency. Liprolog – EPAR, Product Information (Detailed information on this medicinal product is available ). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/liprolog-epar-product-information_en.pdf
  3. European Medicines Agency. Lyumjev (previously Liumjev) – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/lyumjev-epar-product-information_en.pdf
  4. Wikidata (CC0): ATC A10AB.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.